世界の去勢抵抗性前立腺がん（CRPC）/ HRPCA治療薬市場規模・現状・予測（2021年-2027年）

• 英文タイトル：Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size, Status and Forecast 2021-2027

• レポートコード：QFJ1-3977 • 出版社/出版日：QYResearch / 2021年6月 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、97ページ • 納品方法：Eメール（納期：3日） • 産業分類：医療

• 販売価格（消費税別）

Single User	￥585,000 (USD3,900)	▷ お問い合わせ
Multi User	￥877,500 (USD5,850)	▷ お問い合わせ

• ご注文方法：お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法：銀行振込（納品後、ご請求書送付）

---

レポート概要

---

QYResearch社発行の本調査レポートでは、去勢抵抗性前立腺がん（CRPC）/ HRPCA治療薬の世界市場（2016年～2027年）を対象に調査し、市場動向、主要企業の市場シェア、種類別市場規模（経口療法、注射療法）、用途別市場規模（病院＆診療所、家庭用、外来手術センター（ASC））、主要地域別市場規模（北米、アメリカ、欧州、アジア、日本、中国、韓国、インド、東南アジア、中南米、中東、アフリカ等）、企業情報などをまとめております。 ・市場概要 ・去勢抵抗性前立腺がん（CRPC）/ HRPCA治療薬の市場動向 ・企業の競争状況、市場シェア ・去勢抵抗性前立腺がん（CRPC）/ HRPCA治療薬の種類別市場規模と予測2016-2027（経口療法、注射療法） ・去勢抵抗性前立腺がん（CRPC）/ HRPCA治療薬の用途別市場規模と予測2016-2027（病院＆診療所、家庭用、外来手術センター（ASC）） ・去勢抵抗性前立腺がん（CRPC）/ HRPCA治療薬の北米市場規模2016-2027（アメリカ、カナダ） ・去勢抵抗性前立腺がん（CRPC）/ HRPCA治療薬の欧州市場規模2016-2027（ドイツ、フランス、イギリス等） ・去勢抵抗性前立腺がん（CRPC）/ HRPCA治療薬のアジア市場規模2016-2027（日本、中国、韓国、インド、東南アジア等） ・去勢抵抗性前立腺がん（CRPC）/ HRPCA治療薬の中南米市場規模2016-2027（メキシコ、ブラジル） ・去勢抵抗性前立腺がん（CRPC）/ HRPCA治療薬の中東・アフリカ市場規模2016-2027（トルコ、サウジアラビア等） ・主要企業情報（Astellas Inc.、Johnson & Johnson、Sanofi S.A、Dendreon Corporation、Bayer AG） ・結論

Castration-Resistant Prostate Cancer (CRPC) or Hormone Refractory Prostate Cancer (CRPC), a type of prostate cancer that typically recurs after administering androgen deprivation therapy (ADT), is gaining prominence in the prostate cancer market. The global CRPC market is poised to expand at a significant pace, owing to high unmet clinical need, limited survival benefits, growing prevalence rates and fast emerging treatment modifications. The market growth would pivot around the novel breakthrough treatments responsible for reaping survival benefits. The survival benefit would be instrumental in governing the peak sales and market penetration of novel approved drugs.

Promising drug pipeline, evolving treatment patterns, emerging untapped non-metastatic CRPC space and augmented patient awareness are the factors that are expected to boost the market growth. Further, untapped CRPC market in the Asia-Pacific and LAMEA region would also accelerate the overall market growth during the forecast period. Untapped non-metastatic CRPC settings would further bolster the market growth. On the other hand, factors such as premium pricing of CRPC drugs, uncertain reimbursement policies and lack of differentiation in mechanism of action among the approved and novel agents are likely to curtail the market growth.
The market would gain traction in the developing regions of Asia-Pacific and third-world countries such as Africa and Latin America. The large undiagnosed patient population, rapid urbanization, rising disposable income, improved government funding towards cancer and growing awareness about prostate cancer would be some of the prime reasons responsible for the unparalleled market growth in these regions. However, oncologists/urologists reluctance towards adoption of these premium treatments in countries like India and China would continue to remain a key challenge for the leading innovators.

Market Analysis and Insights: Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market
The global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics market size is projected to reach US$ 11190 million by 2027, from US$ 7633.6 million in 2020, at a CAGR of 5.2% during 2021-2027.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics market in terms of revenue.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics market.

Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Scope and Market Size
Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2016-2027.

Segment by Type
Oral Therapy
Injectable Therapy

Segment by Application
Hospitals & Clinics
Home Settings
Ambulatory Surgical Centers (ASCs)

By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA

By Company
Astellas Inc.
Johnson & Johnson
Sanofi S.A
Dendreon Corporation
Bayer AG

レポート目次

---

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size Growth Rate by Type: 2016 VS 2021 VS 2027
1.2.2 Oral Therapy
1.2.3 Injectable Therapy
1.3 Market by Application
1.3.1 Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Share by Application: 2016 VS 2021 VS 2027
1.3.2 Hospitals & Clinics
1.3.3 Home Settings
1.3.4 Ambulatory Surgical Centers (ASCs)
1.4 Study Objectives
1.5 Years Considered

2 Global Growth Trends
2.1 Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Perspective (2016-2027)
2.2 Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Growth Trends by Regions
2.2.1 Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size by Regions: 2016 VS 2021 VS 2027
2.2.2 Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Historic Market Share by Regions (2016-2021)
2.2.3 Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Forecasted Market Size by Regions (2022-2027)
2.3 Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Industry Dynamic
2.3.1 Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Trends
2.3.2 Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Drivers
2.3.3 Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Challenges
2.3.4 Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Restraints

3 Competition Landscape by Key Players
3.1 Global Top Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Players by Revenue
3.1.1 Global Top Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Players by Revenue (2016-2021)
3.1.2 Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue Market Share by Players (2016-2021)
3.2 Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Players Covered: Ranking by Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue
3.4 Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Concentration Ratio
3.4.1 Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue in 2020
3.5 Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Key Players Head office and Area Served
3.6 Key Players Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Product Solution and Service
3.7 Date of Enter into Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market
3.8 Mergers & Acquisitions, Expansion Plans

4 Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Breakdown Data by Type
4.1 Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Historic Market Size by Type (2016-2021)
4.2 Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Forecasted Market Size by Type (2022-2027)

5 Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Breakdown Data by Application
5.1 Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Historic Market Size by Application (2016-2021)
5.2 Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Forecasted Market Size by Application (2022-2027)

6 North America
6.1 North America Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size (2016-2027)
6.2 North America Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size by Type
6.2.1 North America Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size by Type (2016-2021)
6.2.2 North America Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size by Type (2022-2027)
6.2.3 North America Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size by Type (2016-2027)
6.3 North America Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size by Application
6.3.1 North America Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size by Application (2016-2021)
6.3.2 North America Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size by Application (2022-2027)
6.3.3 North America Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size by Application (2016-2027)
6.4 North America Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size by Country
6.4.1 North America Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size by Country (2016-2021)
6.4.2 North America Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size by Country (2022-2027)
6.4.3 United States
6.4.4 Canada

7 Europe
7.1 Europe Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size (2016-2027)
7.2 Europe Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size by Type
7.2.1 Europe Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size by Type (2016-2021)
7.2.2 Europe Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size by Type (2022-2027)
7.2.3 Europe Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size by Type (2016-2027)
7.3 Europe Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size by Application
7.3.1 Europe Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size by Application (2016-2021)
7.3.2 Europe Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size by Application (2022-2027)
7.3.3 Europe Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size by Application (2016-2027)
7.4 Europe Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size by Country
7.4.1 Europe Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size by Country (2016-2021)
7.4.2 Europe Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size by Country (2022-2027)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic

8 Asia-Pacific
8.1 Asia-Pacific Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size (2016-2027)
8.2 Asia-Pacific Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size by Type
8.2.1 Asia-Pacific Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size by Type (2016-2021)
8.2.2 Asia-Pacific Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size by Type (2022-2027)
8.2.3 Asia-Pacific Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size by Type (2016-2027)
8.3 Asia-Pacific Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size by Application
8.3.1 Asia-Pacific Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size by Application (2016-2021)
8.3.2 Asia-Pacific Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size by Application (2022-2027)
8.3.3 Asia-Pacific Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size by Application (2016-2027)
8.4 Asia-Pacific Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size by Region
8.4.1 Asia-Pacific Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size by Region (2016-2021)
8.4.2 Asia-Pacific Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size by Region (2022-2027)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia

9 Latin America
9.1 Latin America Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size (2016-2027)
9.2 Latin America Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size by Type
9.2.1 Latin America Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size by Type (2016-2021)
9.2.2 Latin America Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size by Type (2022-2027)
9.2.3 Latin America Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size by Type (2016-2027)
9.3 Latin America Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size by Application
9.3.1 Latin America Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size by Application (2016-2021)
9.3.2 Latin America Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size by Application (2022-2027)
9.3.3 Latin America Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size by Application (2016-2027)
9.4 Latin America Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size by Country
9.4.1 Latin America Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size by Country (2016-2021)
9.4.2 Latin America Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size by Country (2022-2027)
9.4.3 Mexico
9.4.4 Brazil

10 Middle East & Africa
10.1 Middle East & Africa Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size (2016-2027)
10.2 Middle East & Africa Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size by Type
10.2.1 Middle East & Africa Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size by Type (2016-2021)
10.2.2 Middle East & Africa Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size by Type (2022-2027)
10.2.3 Middle East & Africa Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size by Type (2016-2027)
10.3 Middle East & Africa Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size by Application
10.3.1 Middle East & Africa Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size by Application (2016-2021)
10.3.2 Middle East & Africa Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size by Application (2022-2027)
10.3.3 Middle East & Africa Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size by Application (2016-2027)
10.4 Middle East & Africa Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size by Country
10.4.1 Middle East & Africa Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size by Country (2016-2021)
10.4.2 Middle East & Africa Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size by Country (2022-2027)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE

11 Key Players Profiles
11.1 Astellas Inc.
11.1.1 Astellas Inc. Company Details
11.1.2 Astellas Inc. Business Overview
11.1.3 Astellas Inc. Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Introduction
11.1.4 Astellas Inc. Revenue in Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Business (2016-2021)
11.1.5 Astellas Inc. Recent Development
11.2 Johnson & Johnson
11.2.1 Johnson & Johnson Company Details
11.2.2 Johnson & Johnson Business Overview
11.2.3 Johnson & Johnson Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Introduction
11.2.4 Johnson & Johnson Revenue in Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Business (2016-2021)
11.2.5 Johnson & Johnson Recent Development
11.3 Sanofi S.A
11.3.1 Sanofi S.A Company Details
11.3.2 Sanofi S.A Business Overview
11.3.3 Sanofi S.A Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Introduction
11.3.4 Sanofi S.A Revenue in Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Business (2016-2021)
11.3.5 Sanofi S.A Recent Development
11.4 Dendreon Corporation
11.4.1 Dendreon Corporation Company Details
11.4.2 Dendreon Corporation Business Overview
11.4.3 Dendreon Corporation Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Introduction
11.4.4 Dendreon Corporation Revenue in Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Business (2016-2021)
11.4.5 Dendreon Corporation Recent Development
11.5 Bayer AG
11.5.1 Bayer AG Company Details
11.5.2 Bayer AG Business Overview
11.5.3 Bayer AG Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Introduction
11.5.4 Bayer AG Revenue in Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Business (2016-2021)
11.5.5 Bayer AG Recent Development

12 Analyst’s Viewpoints/Conclusions

13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

List of Tables
Table 1. Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size Growth Rate by Type (US$ Million):2016 VS 2021 VS 2027
Table 2. Key Players of Oral Therapy
Table 3. Key Players of Injectable Therapy
Table 4. Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size Growth by Application (US$ Million): 2016 VS 2021 VS 2027
Table 5. Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size by Regions (US$ Million): 2016 VS 2021 VS 2027
Table 6. Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size by Regions (2016-2021) & (US$ Million)
Table 7. Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Share by Regions (2016-2021)
Table 8. Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Forecasted Market Size by Regions (2022-2027) & (US$ Million)
Table 9. Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Share by Regions (2022-2027)
Table 10. Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Trends
Table 11. Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Drivers
Table 12. Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Challenges
Table 13. Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Restraints
Table 14. Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue by Players (2016-2021) & (US$ Million)
Table 15. Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Share by Players (2016-2021)
Table 16. Global Top Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics as of 2020)
Table 17. Ranking of Global Top Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Companies by Revenue (US$ Million) in 2020
Table 18. Global 5 Largest Players Market Share by Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue (CR5 and HHI) & (2016-2021)
Table 19. Key Players Headquarters and Area Served
Table 20. Key Players Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Product Solution and Service
Table 21. Date of Enter into Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market
Table 22. Mergers & Acquisitions, Expansion Plans
Table 23. Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size by Type (2016-2021) (US$ Million)
Table 24. Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue Market Share by Type (2016-2021)
Table 25. Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Forecasted Market Size by Type (2022-2027) (US$ Million)
Table 26. Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue Market Share by Type (2022-2027) & (US$ Million)
Table 27. Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size Share by Application (2016-2021) & (US$ Million)
Table 28. Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue Market Share by Application (2016-2021)
Table 29. Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Forecasted Market Size by Application (2022-2027) (US$ Million)
Table 30. Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue Market Share by Application (2022-2027) & (US$ Million)
Table 31. North America Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size by Type (2016-2021) (US$ Million)
Table 32. North America Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size by Type (2022-2027) & (US$ Million)
Table 33. North America Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size by Application (2016-2021) (US$ Million)
Table 34. North America Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size by Application (2022-2027) & (US$ Million)
Table 35. North America Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size by Country (2016-2021) & (US$ Million)
Table 36. North America Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size by Country (2022-2027) & (US$ Million)
Table 37. Europe Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size by Type (2016-2021) (US$ Million)
Table 38. Europe Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size by Type (2022-2027) & (US$ Million)
Table 39. Europe Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size by Application (2016-2021) (US$ Million)
Table 40. Europe Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size by Application (2022-2027) & (US$ Million)
Table 41. Europe Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size by Country (2016-2021) & (US$ Million)
Table 42. Europe Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size by Country (2022-2027) & (US$ Million)
Table 43. Asia-Pacific Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size by Type (2016-2021) (US$ Million)
Table 44. Asia-Pacific Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size by Type (2022-2027) & (US$ Million)
Table 45. Asia-Pacific Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size by Application (2016-2021) (US$ Million)
Table 46. Asia-Pacific Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size by Application (2022-2027) & (US$ Million)
Table 47. Asia-Pacific Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size by Region (2016-2021) & (US$ Million)
Table 48. Asia-Pacific Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size by Region (2022-2027) & (US$ Million)
Table 49. Latin America Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size by Type (2016-2021) (US$ Million)
Table 50. Latin America Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size by Type (2022-2027) & (US$ Million)
Table 51. Latin America Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size by Application (2016-2021) (US$ Million)
Table 52. Latin America Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size by Application (2022-2027) & (US$ Million)
Table 53. Latin America Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size by Country (2016-2021) & (US$ Million)
Table 54. Latin America Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size by Country (2022-2027) & (US$ Million)
Table 55. Middle East & Africa Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size by Type (2016-2021) (US$ Million)
Table 56. Middle East & Africa Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size by Type (2022-2027) & (US$ Million)
Table 57. Middle East & Africa Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size by Application (2016-2021) (US$ Million)
Table 58. Middle East & Africa Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size by Application (2022-2027) & (US$ Million)
Table 59. Middle East & Africa Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size by Country (2016-2021) & (US$ Million)
Table 60. Middle East & Africa Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size by Country (2022-2027) & (US$ Million)
Table 61. Astellas Inc. Company Details
Table 62. Astellas Inc. Business Overview
Table 63. Astellas Inc. Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Product
Table 64. Astellas Inc. Revenue in Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Business (2016-2021) & (US$ Million)
Table 65. Astellas Inc. Recent Development
Table 66. Johnson & Johnson Company Details
Table 67. Johnson & Johnson Business Overview
Table 68. Johnson & Johnson Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Product
Table 69. Johnson & Johnson Revenue in Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Business (2016-2021) & (US$ Million)
Table 70. Johnson & Johnson Recent Development
Table 71. Sanofi S.A Company Details
Table 72. Sanofi S.A Business Overview
Table 73. Sanofi S.A Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Product
Table 74. Sanofi S.A Revenue in Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Business (2016-2021) & (US$ Million)
Table 75. Sanofi S.A Recent Development
Table 76. Dendreon Corporation Company Details
Table 77. Dendreon Corporation Business Overview
Table 78. Dendreon Corporation Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Product
Table 79. Dendreon Corporation Revenue in Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Business (2016-2021) & (US$ Million)
Table 80. Dendreon Corporation Recent Development
Table 81. Bayer AG Company Details
Table 82. Bayer AG Business Overview
Table 83. Bayer AG Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Product
Table 84. Bayer AG Revenue in Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Business (2016-2021) & (US$ Million)
Table 85. Bayer AG Recent Development
Table 86. Research Programs/Design for This Report
Table 87. Key Data Information from Secondary Sources
Table 88. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Share by Type: 2020 VS 2027
Figure 2. Oral Therapy Features
Figure 3. Injectable Therapy Features
Figure 4. Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Share by Application: 2020 VS 2027
Figure 5. Hospitals & Clinics Case Studies
Figure 6. Home Settings Case Studies
Figure 7. Ambulatory Surgical Centers (ASCs) Case Studies
Figure 8. Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Report Years Considered
Figure 9. Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size (US$ Million), Year-over-Year: 2016-2027
Figure 10. Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size (US$ Million), 2016 VS 2021 VS 2027
Figure 11. Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Share by Regions: 2020 VS 2027
Figure 12. Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Share by Regions (2022-2027)
Figure 13. Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Share by Players in 2020
Figure 14. Global Top Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics as of 2020
Figure 15. The Top 10 and 5 Players Market Share by Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue in 2020
Figure 16. Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue Market Share by Type (2016-2021)
Figure 17. Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue Market Share by Type (2022-2027)
Figure 18. North America Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 19. North America Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Share by Type (2016-2027)
Figure 20. North America Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Share by Application (2016-2027)
Figure 21. North America Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Share by Country (2016-2027)
Figure 22. United States Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 23. Canada Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 24. Europe Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 25. Europe Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Share by Type (2016-2027)
Figure 26. Europe Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Share by Application (2016-2027)
Figure 27. Europe Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Share by Country (2016-2027)
Figure 28. Germany Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 29. France Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 30. U.K. Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 31. Italy Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 32. Russia Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 33. Nordic Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 34. Asia-Pacific Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 35. Asia-Pacific Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Share by Type (2016-2027)
Figure 36. Asia-Pacific Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Share by Application (2016-2027)
Figure 37. Asia-Pacific Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Share by Region (2016-2027)
Figure 38. China Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 39. Japan Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 40. South Korea Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 41. Southeast Asia Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 42. India Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 43. Australia Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 44. Latin America Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 45. Latin America Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Share by Type (2016-2027)
Figure 46. Latin America Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Share by Application (2016-2027)
Figure 47. Latin America Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Share by Country (2016-2027)
Figure 48. Mexico Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 49. Brazil Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 50. Middle East & Africa Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 51. Middle East & Africa Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Share by Type (2016-2027)
Figure 52. Middle East & Africa Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Share by Application (2016-2027)
Figure 53. Middle East & Africa Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Share by Country (2016-2027)
Figure 54. Turkey Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 55. Saudi Arabia Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 56. UAE Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 57. Astellas Inc. Revenue Growth Rate in Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Business (2016-2021)
Figure 58. Johnson & Johnson Revenue Growth Rate in Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Business (2016-2021)
Figure 59. Sanofi S.A Revenue Growth Rate in Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Business (2016-2021)
Figure 60. Dendreon Corporation Revenue Growth Rate in Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Business (2016-2021)
Figure 61. Bayer AG Revenue Growth Rate in Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Business (2016-2021)
Figure 62. Bottom-up and Top-down Approaches for This Report
Figure 63. Data Triangulation
Figure 64. Key Executives Interviewed

---